Literature DB >> 30718316

Clinical application of the sentinel lymph node technique in early ovarian cancer: a pilot study.

V Lago1, P Bello2, B Montero3, L Matute4, P Padilla-Iserte4, S Lopez3, M Agudelo2, S Domingo4.   

Abstract

INTRODUCTION: There is limited evidence favoring the use of the sentinel lymph node technique in ovarian cancer, and no standardized approach has been studied. The objective of the present pilot study is to determine the feasibility of the sentinel lymph node technique by applying a clinical algorithm.
METHODS: Patients with confirmed ovarian cancer were included. 99mTc and indocyanine green were injected into the ovarian and infundubulo-pelvic ligament stump. A gamma probe and near-infrared fluorescence imaging were used for sentinel lymph node detection.
RESULTS: The sentinel lymph node technique was performed in nine patients with a detection rate in the pelvic and/or para-aortic region of 100%. The tracer distribution rates of sentinel lymph nodes in the pelvic and para-aortic regions were 87.5% and 70%, respectively.
CONCLUSION: The detection of sentinel lymph nodes in early-stage ovarian cancer appears to be achievable. Based on these results, a clinical trial entitled SENTOV (SENtinel lymph node Technique in OVarian cancer) will be performed. © IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  early stage; ovarian cancer; sentinel lymph node; staging

Mesh:

Substances:

Year:  2018        PMID: 30718316     DOI: 10.1136/ijgc-2018-000049

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

Review 1.  IGCS Intraoperative Technology Taskforce. Update on near infrared imaging technology: beyond white light and the naked eye, indocyanine green and near infrared technology in the treatment of gynecologic cancers.

Authors:  Nadeem R Abu-Rustum; Roberto Angioli; Arthur E Bailey; Vance Broach; Alessandro Buda; Michelle R Coriddi; Joseph H Dayan; Michael Frumovitz; Yong Man Kim; Rainer Kimmig; Mario M Leitao; Mustafa Zelal Muallem; Matt McKittrick; Babak Mehrara; Roberto Montera; Lea A Moukarzel; Raj Naik; Silvana Pedra Nobre; Marie Plante; Francesco Plotti; Oliver Zivanovic
Journal:  Int J Gynecol Cancer       Date:  2020-03-30       Impact factor: 3.437

2.  Sentinel lymph node technique in early-stage ovarian cancer (SENTOV): a phase II clinical trial.

Authors:  Victor Lago; Pilar Bello; Beatriz Montero; Luis Matute; Pablo Padilla-Iserte; Susana Lopez; Tiermes Marina; Marc Agudelo; Santiago Domingo
Journal:  Int J Gynecol Cancer       Date:  2020-05-23       Impact factor: 3.437

3.  Sentinel lymph node identification in early stage ovarian cancer: is it still possible after prior tumor resection?

Authors:  Pim Laven; Roy Kruitwagen; Petra Zusterzeel; Brigitte Slangen; Toon van Gorp; Jochem van der Pol; Sandrina Lambrechts
Journal:  J Ovarian Res       Date:  2021-10-13       Impact factor: 4.234

4.  Axillary lymph-node metastases as the primary presentation of high-grade serous ovarian carcinoma: A case report.

Authors:  Monire Mirzaei; Abbas Eshraghi; Mahdiieh Ghoddoosi; Maedeh Alsadat Fatemi; Azhar Eshraghi; Sara Shenavaei; Danial Fazilat-Panah
Journal:  Clin Case Rep       Date:  2022-04-14

5.  Feasibility of sentinel lymph node mapping in ovarian tumors: A systematic review and meta-analysis of the literature.

Authors:  Saeideh Ataei Nakhaei; Sayyed Mostafa Mostafavi; Marjaneh Farazestanian; Malihe Hassanzadeh; Ramin Sadeghi
Journal:  Front Med (Lausanne)       Date:  2022-08-01

6.  Utility of Intraoperative Fluorescence Imaging in Gynecologic Surgery: Systematic Review and Consensus Statement.

Authors:  Ignacio Zapardiel; Julio Alvarez; Manel Barahona; Pere Barri; Ana Boldo; Pera Bresco; Isabel Gasca; Ibon Jaunarena; Ali Kucukmetin; Gloria Mancebo; Borja Otero; Fernando Roldan; Ramón Rovira; Enma Suarez; Alvaro Tejerizo; Anna Torrent; Mikel Gorostidi
Journal:  Ann Surg Oncol       Date:  2020-10-23       Impact factor: 5.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.